Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2019’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H1N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abzyme Therapeutics LLC

Adimmune Corp

Akshaya Bio Inc

Alla Chem LLC

Allergy Therapeutics Plc

Altimmune Inc

Ansun Biopharma Inc

Asavi Llc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

BlueWillow Biologics Inc

Brandenburg Antiinfektiva GmbH

BunyaVax BV

CEL-SCI Corp

Changchun Bcht Biotechnology Co Ltd

Chicago Biosolutions Inc

CHO Pharma Inc

Cidara Therapeutics Inc

Cilian AG

Cocrystal Pharma Inc

Curevac AG

Cytocom Inc

Dnarx LLC

Emergent BioSolutions Inc

Ena Therapeutics Pty Ltd

EpiVax Inc

Etubics Corp

FluGen Inc

Gamma Vaccines Pty Ltd

Genentech Inc

GlaxoSmithKline Plc

Greffex Inc

i2 Pharmaceuticals Inc

ILiAD Biotechnologies LLC

Imutex Ltd

InvVax Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kineta Inc

Mayly Life Sciences

Medicago Inc

Microbiotix Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

OPKO Health Inc

PeptiDream Inc

Recce Ltd

Sanofi Pasteur SA

Sciogen Inc

Seqirus Ltd

Serum Institute of India Ltd

TechnoVax Inc

Tiba Biotech LLC

Touchlight Genetics Ltd

UMN Pharma Inc

Vaccibody AS

Vacthera BioTech GmbH

Vaxart Inc

Vaxxas Pty Ltd

Viramatix Sdn Bhd

Virion Biotherapeutics

Vironova Medical AB

Virvio Inc

Visterra Inc

Vivaldi Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H1N1 Subtype Infections - Overview

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development

AbbVie Inc

Abzyme Therapeutics LLC

Adimmune Corp

Akshaya Bio Inc

Alla Chem LLC

Allergy Therapeutics Plc

Altimmune Inc

Ansun Biopharma Inc

Asavi Llc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

BlueWillow Biologics Inc

Brandenburg Antiinfektiva GmbH

BunyaVax BV

CEL-SCI Corp

Changchun Bcht Biotechnology Co Ltd

Chicago Biosolutions Inc

CHO Pharma Inc

Cidara Therapeutics Inc

Cilian AG

Cocrystal Pharma Inc

Curevac AG

Cytocom Inc

Dnarx LLC

Emergent BioSolutions Inc

Ena Therapeutics Pty Ltd

EpiVax Inc

Etubics Corp

FluGen Inc

Gamma Vaccines Pty Ltd

Genentech Inc

GlaxoSmithKline Plc

Greffex Inc

i2 Pharmaceuticals Inc

ILiAD Biotechnologies LLC

Imutex Ltd

InvVax Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kineta Inc

Mayly Life Sciences

Medicago Inc

Microbiotix Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

OPKO Health Inc

PeptiDream Inc

Recce Ltd

Sanofi Pasteur SA

Sciogen Inc

Seqirus Ltd

Serum Institute of India Ltd

TechnoVax Inc

Tiba Biotech LLC

Touchlight Genetics Ltd

UMN Pharma Inc

Vaccibody AS

Vacthera BioTech GmbH

Vaxart Inc

Vaxxas Pty Ltd

Viramatix Sdn Bhd

Virion Biotherapeutics

Vironova Medical AB

Virvio Inc

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H1N1 Subtype Infections - Drug Profiles

(oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Afluria Quadrivalent - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHOS-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CiFlu - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-7302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAS-181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diridavumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Flu-v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluad (Quadrivalent) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fludase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluzone QIV HD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GHB-11L1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GREFLU/CAL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H1N1 [A/Aichi/2/68] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-36.6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H1N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/Michigan/45/2015 (H1N1)] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/Puerto Rico/8/1934 [H1N1]] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain H1N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1+A/H3N2+B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LEAPS-H1N1-DC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2546 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MC-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDG-2271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metenkefalin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAS-911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasovax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nucleozin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Influenza A Virus H1N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pimodivir hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RECCE-327 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDEE FLU - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Neuraminidase for Influenza A Virus, H1N1 Subtype Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for RSV and Influenza A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block M2 Channel for Influenza A Virus, H1N1 Subtype Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Staphylococcus Aureus Infections and H1N1 Influenza - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VH-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMTX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNFC-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNFC-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTH-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXAA-1.1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WLBU-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H1N1 Subtype Infections - Dormant Projects

Influenza A Virus, H1N1 Subtype Infections - Discontinued Products

Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones

Featured News & Press Releases

Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

Oct 16, 2019: Novavax begins Phase III clinical trial for influenza vaccine NanoFlu

Jun 27, 2019: Novavax confirms accelerated approval pathway available for licensure of Nanoflu

Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.

Mar 29, 2019: hVIVO and Imutex to present at the Influenza Vaccines for the World (IVW 2019) conference at the Royal College of Physicians of Edinburgh, Scotland

Jan 10, 2019: HVIVO reports that the Phase IIb viral challenge Study for FLU-v (FLU-v004) achieved the primary endpoint of a statistically significant reduction in mild to moderate influenza

Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults

Nov 28, 2018: Vaxart to present at World Vaccine and Immunotherapy Congress West Coast 2018

Nov 05, 2018: UNC researchers develop platform for universal Flu Vaccine

Sep 27, 2018: Novavax starts Phase ll trial of NanoFlu for seasonal influenza

Sep 25, 2018: AstraZeneca ships FLUMIST QUADRIVALENT vaccine in the US for 2018-2019 flu season

Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO

Sep 04, 2018: Altimmune announces additional positive data from its phase 2a study of NasoVAX Intranasal Influenza Vaccine

Jun 18, 2018: hVIVO reports positive results from the Phase IIb field study of FLU-v (FLU-v 003) representing a significant advance in the management of influenza disease

Apr 04, 2018: Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Universities/Institutes, H2 2019

Table 7: Products under Development by Companies, H2 2019

Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 12: Products under Development by Universities/Institutes, H2 2019

Table 13: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 14: Number of Products by Stage and Target, H2 2019

Table 15: Number of Products by Stage and Mechanism of Action, H2 2019

Table 16: Number of Products by Stage and Route of Administration, H2 2019

Table 17: Number of Products by Stage and Molecule Type, H2 2019

Table 18: Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc, H2 2019

Table 19: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Abzyme Therapeutics LLC, H2 2019

Table 20: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Adimmune Corp, H2 2019

Table 21: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H2 2019

Table 22: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Alla Chem LLC, H2 2019

Table 23: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Allergy Therapeutics Plc, H2 2019

Table 24: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Altimmune Inc, H2 2019

Table 25: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Ansun Biopharma Inc, H2 2019

Table 26: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Asavi Llc, H2 2019

Table 27: Influenza A Virus, H1N1 Subtype Infections – Pipeline by AstraZeneca Plc, H2 2019

Table 28: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019

Table 29: Influenza A Virus, H1N1 Subtype Infections – Pipeline by BlueWillow Biologics Inc, H2 2019

Table 30: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Brandenburg Antiinfektiva GmbH, H2 2019

Table 31: Influenza A Virus, H1N1 Subtype Infections – Pipeline by BunyaVax BV, H2 2019

Table 32: Influenza A Virus, H1N1 Subtype Infections – Pipeline by CEL-SCI Corp, H2 2019

Table 33: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2019

Table 34: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Chicago Biosolutions Inc, H2 2019

Table 35: Influenza A Virus, H1N1 Subtype Infections – Pipeline by CHO Pharma Inc, H2 2019

Table 36: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cidara Therapeutics Inc, H2 2019

Table 37: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cilian AG, H2 2019

Table 38: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H2 2019

Table 39: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Curevac AG, H2 2019

Table 40: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cytocom Inc, H2 2019

Table 41: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Dnarx LLC, H2 2019

Table 42: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Emergent BioSolutions Inc, H2 2019

Table 43: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Ena Therapeutics Pty Ltd, H2 2019

Table 44: Influenza A Virus, H1N1 Subtype Infections – Pipeline by EpiVax Inc, H2 2019

Table 45: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Etubics Corp, H2 2019

Table 46: Influenza A Virus, H1N1 Subtype Infections – Pipeline by FluGen Inc, H2 2019

Table 47: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Gamma Vaccines Pty Ltd, H2 2019

Table 48: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Genentech Inc, H2 2019

Table 49: Influenza A Virus, H1N1 Subtype Infections – Pipeline by GlaxoSmithKline Plc, H2 2019

Table 50: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Greffex Inc, H2 2019

Table 51: Influenza A Virus, H1N1 Subtype Infections – Pipeline by i2 Pharmaceuticals Inc, H2 2019

Table 52: Influenza A Virus, H1N1 Subtype Infections – Pipeline by ILiAD Biotechnologies LLC, H2 2019

Table 53: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Imutex Ltd, H2 2019

Table 54: Influenza A Virus, H1N1 Subtype Infections – Pipeline by InvVax Inc, H2 2019

Table 55: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019

Table 56: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Johnson & Johnson, H2 2019

Table 57: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kineta Inc, H2 2019

Table 58: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Mayly Life Sciences, H2 2019

Table 59: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Medicago Inc, H2 2019

Table 60: Influenza A Virus, H1N1 Subtype Infections – Pipeline by Microbiotix Inc, H2 2019

List of Figures

List of Figures

Figure 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports